|Day Low/High||2.90 / 3.05|
|52 Wk Low/High||1.95 / 4.08|
Unless there is a dilution event around the corner, the selloff is overdone.
We'll purchase more shares of Pixelworks and Inovio ahead of their quarterly results next week.
- Study Objective Achieved with 2.2% of Patients Experiencing a Device Error -
We made several trades and price target changes during a mixed week for the portfolio.
Sometimes, changing the price target is better than selling (or buying).
The portfolio has some high fliers and underperformers last week as we head into the heart of earnings season.
Investors in AcelRx Pharmaceuticals Inc saw new options begin trading today, for the March 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
We brought a new name into the portfolio last week as the Fed's comments helped lift the market.
We made no trades during the holiday-shortened week, but added to our natural hedge today.
We added a name to the portfolio's Bullpen as a whirlwind quarter came to an end.
We exited 2 positions and took some profits during a busy week for the portfolio.
We initiated a new position and made several other trades during a week of twists and turns.
We initiated 2 new positions in a week dominated by political events.
We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.
We scaled further into one position and added a Bullpen name as the market shrugged off geopolitical uncertainties.
It was a busy week of moves in the portfolio as we head into the latter half of the second quarter.
AcelRx Pharmaceuticals is another interesting, yet speculative, play.